Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.

Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima M.

Thromb Haemost. 2013 Jun;109(6):1007-15. doi: 10.1160/TH12-10-0762.

PMID:
23467620
2.

Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.

Ninivaggi M, Dargaud Y, van Oerle R, de Laat B, Hemker HC, Lindhout T.

J Thromb Haemost. 2011 Aug;9(8):1549-55. doi: 10.1111/j.1538-7836.2011.04358.x.

3.

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.

Yada K, Nogami K, Takeyama M, Ogiwara K, Wakabayashi H, Shima M.

J Thromb Haemost. 2015 Oct;13(10):1843-53. doi: 10.1111/jth.13118.

PMID:
26278069
4.
5.

Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.

Gilmore R, Harmon S, Gannon C, Byrne M, O'Donnell JS, Jenkins PV.

Haemophilia. 2010 Jul 1;16(4):671-4. doi: 10.1111/j.1365-2516.2009.02190.x.

PMID:
20148980
6.
7.

Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.

Johnson DJ, Pemberton S, Acquila M, Mori PG, Tuddenham EG, O'Brien DP.

Thromb Haemost. 1994 Apr;71(4):428-33.

PMID:
8052958
8.

A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.

Matsumoto T, Nogami K, Ogiwara K, Shima M.

Int J Hematol. 2009 Dec;90(5):576-82. doi: 10.1007/s12185-009-0450-y.

PMID:
19937483
9.

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.

Bassus S, Wegert W, Krause M, Escuriola-Ettinghausen C, Siegemund A, Petros S, Scholz T, Scharrer I, Kreuz W, Engelmann L, Kirchmaier CM.

Platelets. 2006 Sep;17(6):378-84.

PMID:
16973498
10.

Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.

Pavlova A, Delev D, Pezeshkpoor B, Müller J, Oldenburg J.

Thromb Haemost. 2014 May 5;111(5):851-61. doi: 10.1160/TH13-08-0690.

PMID:
24452774
11.

Functional characteristics of N8, a new recombinant FVIII.

Christiansen ML, Balling KW, Persson E, Hilden I, Bagger-Sørensen A, Sørensen BB, Viuff D, Segel S, Klausen NK, Ezban M, Lethagen S, Steenstrup TD, Kjalke M.

Haemophilia. 2010 Nov;16(6):878-87. doi: 10.1111/j.1365-2516.2010.02333.x.

PMID:
20546031
12.

A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.

Matsumoto T, Nogami K, Ogiwara K, Shima M.

Thromb Haemost. 2012 Feb;107(2):288-301. doi: 10.1160/TH11-05-0331.

PMID:
22234708
13.

The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.

Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, Giles AR, Yoshioka A.

J Thromb Haemost. 2006 Feb;4(2):377-84.

14.

Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation.

Radic CP, Rossetti LC, Abelleyro MM, Tetzlaff T, Candela M, Neme D, Sciuccati G, Bonduel M, Medina-Acosta E, Larripa IB, de Tezanos Pinto M, De Brasi CD.

J Thromb Haemost. 2015 Apr;13(4):530-9. doi: 10.1111/jth.12854.

PMID:
25611311
15.
16.

Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.

Damon AL, Scudder LE, Gnatenko DV, Sitaraman V, Hearing P, Jesty J, Bahou WF.

Thromb Haemost. 2008 Dec;100(6):1111-22.

PMID:
19132238
17.

Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.

Quade-Lyssy P, Abriss D, Milanov P, Ungerer C, Königs C, Seifried E, Schüttrumpf J.

J Thromb Haemost. 2014 Nov;12(11):1861-73. doi: 10.1111/jth.12731.

18.

Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.

Trossaërt M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T.

J Thromb Haemost. 2008 Mar;6(3):486-93.

19.

Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.

Livnat T, Shenkman B, Kenet G, Tamarin I, Gillis S, Varon D, Iijima K, Zivelin A, Salomon O.

Blood Coagul Fibrinolysis. 2011 Dec;22(8):673-9. doi: 10.1097/MBC.0b013e32834ad785.

PMID:
22008904
20.

Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function.

Celie PH, Van Stempvoort G, Jorieux S, Mazurier C, Van Mourik JA, Mertens K.

Br J Haematol. 1999 Sep;106(3):792-800.

PMID:
10468875
Items per page

Supplemental Content

Support Center